tbuckley/cabot-search huggingface dataset:
Panlobular and Centrilobular Emphysema: Correlation of Clinical Findings with Pathologic Patterns.
Authors: H. C. Sweet
Journal: Annals of Internal Medicine (1961)

s1 May 1961Panlobular and Centrilobular Emphysema: Correlation of Clinical Findings with Pathologic Patterns.H. C. Sweet, M.D., F.A.C.P., J. P. Wyatt, M.D., A. J. Fritsch, M.D., P. W. Kinsella, M.D.H. C. Sweet, M.D., F.A.C.P.Search for more papers by this author, J. P. Wyatt, M.D.Search for more papers by this author, A. J. Fritsch, M.D.Search for more papers by this author, P. W. Kinsella, M.D.Search for more papers by this authorAuthor, Article, and Disclosure Informationhttps://doi.org/10.7326/0003-4819-54-5-1060_3 SectionsAboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail ExcerptTwo distinct types of pulmonary emphysema have been recognized by post-mortem examination of the lungs by macrosection technics. Seventy-five such cases (39 centrilobular, 36 panlobular) have been subjected to clinical analysis. Centrilobular emphysema is characterized by distention and destruction of the central part of secondary lung lobules involving the terminal respiratory bronchioles; panlobular (panacinar) by destruction of entire secondary lung lobules.Clinically, three-fourths of centrilobular cases have an insidious onset with dyspnea preceded by cough. The patient is always underweight; blood pressure is normal or low; heart failure occurs in 50% and usually late in the disease. Roentgenographically, heart size... This content is PDF only. To continue reading please click on the PDF icon. Author, Article, and Disclosure InformationAffiliations: St. Louis, Mo. (CS) PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetails Metrics 1 May 1961Volume 54, Issue 5Page: 1060-1061KeywordsAutopsyBlood pressureBronchiolesDyspneaEmphysemaHeartHeart diseasesHeart failureLungs Issue Published: 1 May 1961 PDF downloadLoading ...
Abstract 126: A Case Of Slowly Progressing Giant Coronary Aneurysm In A Patient With Intractable Kawasaki Disease
Authors: Ji Whan Han, Yu Mi Seo, Kyu Jin Lee, Joo Hyun Kim, Jae Young Lee, Jin Hee Oh, Soon Ju Lee
Journal: Circulation (2015)

Background: Some patients with intravenous immunoglobulin (IVIG)-resistant Kawasaki disease (KD) do not respond to intravenous methylprednisolone (IVMP). Infliximab (IFX; anti-TNF-α antibody) is an alternative medication for intractable KD. Its effectiveness in preventing coronary aneurysms from progressing is being reported. We herein report a case of intractable KD that slowly progressed to giant aneurysm despite a second IFX infusion. Methods: A 2-year-old boy visited our hospital with a 2-day history of fever. On day 3 after fever onset, a swollen cervical lymph node, redness of the BCG (bacilli Calmette Guérin) inoculation site, and indurated erythema of the palms with soles were observed. On day 5, conjunctival injection, strawberry tongue, red lips and truncal rash were present. The patient was diagnosed with KD and treated with IVIG and acetylsalicylic acid (ASA). Results: The fever persisted for 24 h after IVIG treatment. A second dose of IVIG was infused. However, the fever continued. Then IVMP was infused. On day 9, the fever resolved. On day 10, two-dimensional echocardiography (2DE) showed mild dilations (Φ 3.0 mm) of both coronary arteries (CAs). On day 18, the fever recurred. Follow-up 2DE showed dilated CAs (left main coronary artery [LM], Φ 4.0 mm; right coronary artery [RCA], Φ 4.0 mm). Therefore, IFX was intravenously infused. On day 19, the fever had resolved and the patient went home. On day 22, the fever recurred. Thus, a second infusion of IFX was done. On day 24, the fever resolved. Follow-up 2DE showed that the diameters of the CAs were 4.0 mm (LM), 7.0 mm (left anterior descending coronary artery [LAD]), 3.0 mm (RCA). On day 28, a mild fever was still present. On day 47, follow-up 2DE indicated that the diameters of the CAs were 3.0 mm (LM), 8.0 mm (LAD), 2.5 mm (RCA). On day 159, follow-up 2DE showed slightly increased regression of CAs. The patient has been undergoing regular 2DE and taking ASA since he left the hospital. Conclusions: This was a very rare case of KD that was resistant to standard treatment comprising high-dose steroids and TNF-α blockade. We have reported this case to inform clinicians who may encounter such patients with KD in the future. A high index of suspicion and keen observations are strongly recommended for cases of intractable KD.
Stroke, orthostatic hypotension, and focal seizures
Authors: T. L. Riley
Journal: JAMA (1981)

A 75-year-old man had development of left hemiparesis after a cerebral infarction. Nine months later, he was admitted to the hospital after a generalized tonic clonic convulsion. In the hospital, he had clonic movement on the left side of the body. Even after acceptable control of orthostatic hypotension, rising from supine to standing position evoked slow waves over the right hemisphere on the EEG tracing. This example of focal seizures with orthostatic hypotension shows that previously compromised cerebral tissue or vessels may be vulnerable to changes in blood pressure. We suggest that convulsive movements associated with hypotension or syncope result from cortical mechanisms rather than brainstem tonic release mechanisms. (<i>JAMA</i>1981;245:1243-1244)
Error in Methods Section
Journal: JAMA Neurology (2018)

Benjamin K. Dawson, BSc; Seyed-Mohammad Fereshtehnejad, MD, MPH, PhD; Julius B. M. Anang, MD, PhD; Takashi Nomura, MD, PhD; Silvia Rios-Romenets, MD; Kenji Nakashima, MD, PhD; Jean-François Gagnon, PhD; Ronald B. Postuma, MD, MSc
Women Physicians
Journal: JAMA (2002)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Editorial: Self-analysis in allied health education
Authors: R. C. Kuhli
Journal: JAMA (1973)

The hospital, college, university, or other institution conducting an allied health education program is itself the best judge of the quality of that program. To assist them in such a self-study analysis the AMA Council on Medical Education provides a "Self-Analysis Outline," which has been developed by the Council's Advisory Committee on Education for the Allied Health Professions and Services and its panel of consultants and special advisors. The chief administrative officer of an institution requesting accreditation for an allied medical education program writes to the AMA Department of Allied Medical Professions and Services. In addition to the traditional pre-survey questionnaire, the institution may now be sent a copy of the "Self-Analysis Outline" and in some cases guidelines for meeting the<i>Essentials</i>which are minimal requirements for AMA accreditation. The "Self-Analysis Outline" and pre-survey questionnaire are used by the chief administrative officer, director, and faculty of the educational program, and
23rd annual meeting of the American Society of Nephrology (ASN). Washington, D.C., December 2-5, 1990. Program and abstracts.
Journal: Journal of the American Society of Nephrology (1990)

Log in or Register Subscribe to journalSubscribe Get new issue alertsGet alerts Enter your Email address: Wolters Kluwer Health may email you for journal alerts and information, but is committed to maintaining your privacy and will not share your personal information without your express consent. For more information, please refer to our Privacy Policy. Subscribe to eTOC Secondary Logo Journal Logo All Articles Images Videos Podcasts Blogs Advanced Search Toggle navigation Subscribe Register Login Articles Current IssuePublished Ahead of Print Subject CollectionsPodcastsArchives Authors Submit to JASNInformation for Authors Journal Info About JASNEditorial TeamEditorial FellowsEditorial Fellowship ApplicationJASN ImpactJASN Recognizes More AlertsAdvertisingSubscriptionsReprints All Articles Images Videos Podcasts Blogs Advanced Search
A phase II study of cabozantinib in patients (pts) with relapsed or refractory metastatic urothelial carcinoma (mUC).
Authors: Andrea B. Apolo, Howard L. Parnes, Deneise C Francis, Lisa M Cordes, Marilise Berninger, Elizabeth Lamping, Rene Costello, Jane B. Trepel, Maria J Merino, Les Folio, Maria Liza Lindenberg, William Douglas Figg, Seth M. Steinberg, John Joseph Wright, Ravi Amrit Madan, Yangmin M. Ning, James L. Gulley, Donald P. Bottaro, William L. Dahut, Piyush K. Agarwal
Journal: Journal of Clinical Oncology (2016)

4534 Background: Hepatocyte growth factor (HGF) and its receptor (MET) are activated in urothelial carcinoma (UC). In translational studies, cabozantinib, a multiple receptor tyrosine kinase inhibitor primarily targeting MET and VEGFR2, reversed HGF-driven UC cell growth and invasion. Methods: In this phase II study, pts received cabozantinib 60 mg/day in 28-day cycles in 3 cohorts: 1) mUC, 2) bone-only mUC, and 3) metastatic rare bladder histology. The primary objective was response rate (RR) by RECIST v1.1. Results: Of67 pts enrolled, 70% were male, median age: 63 (22–82), KPS 80% in 73% of pts. Primary sites: bladder (69%), upper tract (25%), both (6%). No. of prior therapies: 1/2/3/≥4 (range 1–6) in 34/39/16/9% of pts, respectively; 85% had visceral metastases (lung, liver, bone); sites of metastases included LN/lung/bone/liver/soft tissue/carcinomatosis in 69/36/22/17/21/2% of pts, respectively. Grade 3 adverse events (AEs) in ≥ 2 pts: fatigue 9%, HTN 7%, hypophosphatemia 6%, diarrhea 8%, AST/ALT increase 7%, thrombocytopenia 4%, lymphopenia 3%, hyponatremia 3%, and proteinuria 3%. Grade 4 AEs: hypomagnesemia 3% and lipase increase 1%. Cohorts 1/2/3 enrolled 48/6/13 pts, respectively. Of 41 evaluable pts in cohort 1, there was 1 complete response (CR), 7 partial responses (PR) (RR = 19.5%; 95% CI: 8.8–34.9%), 18 stable disease (SD), and 15 progressive disease (PD). Median progression-free survival (mPFS): 3.7 mos (95% CI: 2.3–6.5); 6-month PFS: 38.0% (95% CI: 23.3–52.6%). Median overall survival (mOS): 8.2 mos (95% CI: 5.2–10.3); 6-month OS: 65.1% (95% CI: 48.3–77.6%); 12-month OS: 25.7% (95% CI: 13.0–40.3%). Median follow-up was 23.7 mos. Of 5 evaluable pts in cohort 2, 3 (60%) had improvement by NaF FDG/PET. mPFS: 5.3 mos (95% CI: 1.8–8.3); mOS: 9.3 mos (95% CI: 3.6–12.5). Of 10 evaluable pts in cohort 3, there were 0 CR/PR, 5 SD, and 5 PD. mPFS: 2.9 mos (95% CI: 1.8–3.7); mOS: 4.6 mos (95% CI: 2.6–8.0). Conclusions: Cabozantinib has clinical activity in pts with relapsed or refractory mUC with manageable toxicities. Further studies are underway to correlate responses with MET expression, immune subsets, CTCs, and cytokine and mutational profiles. Clinical trial information: NCT01688999.
Detection of intracolonic lesion by barium contrast enema. The importance of adequate colon preparation to diagnostic accuracy
Authors: C. O. Knutson
Journal: JAMA (1979)

Frequently, the clinical significance of the barium contrast enema is minimal because of inadequate colon preparation prior to examination. The frequency of false-positive routine barium enemas was 17% in 230 consecutive patients who underwent colonoscopy for removal of specific radiographically identified polypoid colon lesions. Initial barium enema inaccuracies were documented with postendoscopic air-contrast radiography in colons that were endoscopically proved to be mechanically clean following a two-day colon preparation. These results suggest that more emphasis on a two-day colon preparation, before the initial barium contrast enema, would substantially reduce the frequency of false-positive interpretations. (<i>JAMA</i>242:2206-2208, 1979)
A WORD AS TO THE INDEX.
Journal: JAMA (1903)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Abstract 1943: A microRNA signature in urinary exosomes for diagnosis of prostate cancer
Authors: Thorarinn Blondal, Anne I. Rasmussen, Anni R. Thomsen, Michael Borre, Jacob Fredsøe, Ditte Andreasen, Torben Falck Ørntoft, Karina D. Sørensen, Peter Mouritzen
Journal: Cancer Research (2016)

Abstract MicroRNAs constitute a class of small cellular noncoding RNAs (typically 19-23 nt) which function as post-transcriptional regulators of gene expression. The involvement of microRNA in both normal development as well as disease is well established and microRNAs are considered important biomarkers in several diseases including cancer. Surprisingly cell free microRNAs are also found in several biofluids where they have been shown to be very stable, most likely because they are protected from degradation by protein complexes and other particles including exosomes. Exosomes are nanovesicles secreted into the extracellular environment by a wide range of cell types under normal and pathological conditions. As the profile of exosomal microRNAs may be a fingerprint of the releasing cell type and because they are released in easily accessible body fluids such as blood and urine, their microRNA content holds potential as biomarkers for early detection of malignancy. We have developed different technologies enabling the detection of prostate cancer microRNA biomarkers in exosomes derived from urine from non-prostate massaged men. The first of these technologies is a highly sensitive LNA™-based qPCR platform for microRNA detection, which enables profiling in biofluids where microRNA levels are extremely low. At this point we have already applied this platform on thousands of biofluid samples including serum/plasma and urine to establish normal reference ranges for circulating microRNAs as well as to identify biomarkers of disease. The second technology is a simple exosome precipitation system which only requires low speed centrifugation to harvest urine exosomes. Our developed technologies was applied to cell-free urine from three different cohorts including individuals with prostate cancer (PCa) and benign prostate hyperplasia, to identify several differentially regulated microRNAs in urine from PCa bearing individuals. PCa specific signatures were obtained by different combinations of these differentially regulated microRNAs. In conclusion, cell free urine samples holds potential as a liquid biopsy source for exosomal microRNA markers in prostate cancer. Data showing that small miRNA signatures (down to two miRNAs) hold strong diagnostic potential in PCa will be presented. Citation Format: Thorarinn Blondal, Anne I. Rasmussen, Anni R. Thomsen, Michael Borre, Jacob Fredsøe, Ditte Andreasen, Torben Falck Ørntoft, Karina D. Sørensen, Peter Mouritzen. A microRNA signature in urinary exosomes for diagnosis of prostate cancer. [abstract]. In: Proceedings of the 107th Annual Meeting of the American Association for Cancer Research; 2016 Apr 16-20; New Orleans, LA. Philadelphia (PA): AACR; Cancer Res 2016;76(14 Suppl):Abstract nr 1943.
Relation between insufficient response to antihypertensive treatment and poor compliance with treatment: a prospective case-control study
Journal: BMJ (2001)

different devices.Further systematic reviews are needed to assess the effectiveness of pressurised metered dose inhalers with or without spacer devices and the effectiveness of training and education about use of inhaler devices.Pragmatic studies are also required to see whether long term compliance is influenced by choice of delivery device.In summary, we found no evidence that alternative inhaler devices are more clinically effective than pressurised metered dose inhalers for delivery of inhaled corticosteroids.Therefore, pressurised metered dose inhalers or the cheapest inhaler device that patients can use adequately should be used as first line treatment.This paper is based on a Cochrane review that is available in the Cochrane Library.As with all Cochrane reviews, the authors have committed to keep this review up to date.
Hearing Aids
Authors: A Tumarkin
Journal: BMJ (1945)

Implementing quantitative signals in a corporate bond portfolio can be challenging owing to high transaction costs, large variations of liquidity across individual bonds, and the requirement to follow a benchmark index. The authors design realistic simulations that illustrate the performance and characteristics of quantitatively managed portfolios of liquid corporate bonds with attractive value and momentum characteristics. They show how to implement a turnover budget to explicitly control rebalancing volumes. Such realistic strategy portfolios have significantly outperformed the Bloomberg Barclays US Corporate Bond Index after transaction costs, with information ratios above 1 since 2007. The results of this study support the case for style factor investing in credit. <b>TOPICS:</b>Performance measurement, portfolio construction, simulations, style investing <b>Key Findings</b> ▪ Relative value and equity momentum styles can be successfully implemented in corporate bond portfolios net of transaction costs. ▪ We explain how to overcome challenges related to identifying liquid tradable securities with attractive value and momentum characteristics, keeping transaction costs in check, and following a benchmark index at the same time. ▪ Index-tracking portfolios that match key exposures of the US Corporate index, but also overweight bonds with attractive value and momentum characteristics, significantly outperformed the benchmark index after transaction costs, with information ratios above 1 since 2007.
LSCT, a novel submaximal cycle test to monitor fatigue and predict cycling performance
Authors: R P Lamberts, J Swart, T D Noakes, M I Lambert
Journal: British Journal of Sports Medicine (2010)

The purpose of this study was to determine the reliability and predictive value of performance parameters measured by a new novel submaximal cycle protocol (also known as the Lamberts and Lambert submaximal cycle test (LSCT)), on peak power and endurance cycling performance in well-trained cyclists. Seventeen well-trained competitive male road racing cyclists completed three peak power output tests (PPO) and three 40-km time trials (40-km TT) after familiarisation. Before each test all cyclists performed the LSCT as their warm-up method. Parameters associated with performance such as power, speed, cadence and rate of perceived exertion (RPE) were measured during the three stages of the test when cyclists rode at workloads coinciding with fixed predetermined heart rates (60%, 80% and 90% of HR max ). Heart rate recovery (HRR) was measured after the final stage of the test. Parameters measured during the second and third stage of the LSCT were highly reliable (intraclass correlation range: R=0.85-1.00) and associated with low typical error of measurements (TEM range: 1.3%-4.4%). Good relationships were found between the LSCT and cycling performance measured by the PPO and 40-km TT tests. Mean power had stronger relationships with measures of cycling performance during the second (r=0.80-0.89) and third stage (r=0.91-0.94) of the LSCT than HRR (r=0.55-0.68). The LSCT is a reliable novel test which is able to predict peak and endurance cycling performance from submaximal power, RPE and HRR in well-trained cyclists. As these parameters are able to detect meaningful changes more accurately than VO 2max , the LSCT has the potential to monitor cycling performance with more precision than other current existing submaximal cycle protocols.
Nature of autoimmune disease sought through treatment
Authors: M. L. Zoler
Journal: JAMA (1984)

Although the mysteries of autoimmune disease are far from solved, more effective treatments may be on the way. Alfred A. Steinberg, MD, chief, Cellular Immunology Laboratory, National Institute of Arthritis, Diabetes, and Digestive and Kidney Diseases (NIADDK), says, for example, that he and colleagues have shown that in mice a single, X-linked gene called<i>xid</i>— —in either the hemizygous or homozygous form—hampers development of a B lymphocyte subset. Mice without these B cells never develop impaired antibody responses or autoimmune disease, despite the presence of other predisposing genetic and environmental influences. Efforts are now under way in his laboratory, says Steinberg, to identify a similar B cell subpopulation in humans that may be involved in autoantibody production. If this subpopulation is distinguished by a surface marker, the cells might be selectively eliminated without disrupting other aspects of the immune system. Such a prospect seems heightened by the findings of
Author’s reply
Authors: Allan J Flach
Journal: Ophthalmology (2001)

It is difficult for me to reply to the comments from Gary Franklin Spitz, MD, JD, because he blatantly advocates using "incomplete or inaccurate information to make individualized decisions," and he trivializes the potential toxicity of corticosteroids all "in the best interest of our patients." Furthermore, he apparently considers the careful analysis of good data "a foolhardy pursuit of the talisman of peer review." This attitude is so contrary to the pursuit of reliable medical information that one cannot help but wonder whether he is currently practicing medicine or law. In either case, "See you in court!"